The picture that emerges from this review certainly allows us to conclude that the vast majority of dopaminergic therapies, with the exception of COMT inhibitors, have an unfavorable profile in terms of inducing or exacerbating orthostatic hypotension or adverse cardiac changes. The gene discussed is COMT; the disease is hypotensive disorder.